<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="22149">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02818491</url>
  </required_header>
  <id_info>
    <org_study_id>CER 217/15</org_study_id>
    <nct_id>NCT02818491</nct_id>
  </id_info>
  <brief_title>Dexamethasone as an Adjuvant to Ropivacaine for the Interscalene Brachial Plexus Block: a Dose-finding</brief_title>
  <official_title>Dexamethasone as an Adjuvant to Ropivacaine for the Interscalene Brachial Plexus Block: a Dose-finding</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Vaudois</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Vaudois</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Shoulder surgery is associated with moderate to severe postoperative pain. Interscalene
      brachial plexus block is considered by many as the gold standard for treating postoperative
      pain and consists of injecting local anaesthetics close to the nerves of the brachial plexus
      in the neck. Duration of analgesia is between eight to twelve hours depending on the type of
      administered drugs. Dexamethasone 4 mg is a steroid routinely injected intravenously in
      anaesthesia for the prophylaxis of postoperative nausea and vomiting. Recently, different
      trials have demonstrated that combining 4 to 8 mg of dexamethasone with local anaesthetics
      for a perineural injection may prolong the duration of analgesia up to 24 hours. In a
      meta-analysis including 29 trials and 1695 patients, investigators have recently
      demonstrated through a meta-regression that a dose of 4 mg is sufficient and represents a
      ceiling dose, without neurological complications. The objective of this multicenter
      randomised controlled double-blinded trial is to determine the optimal dose of perineural
      dexamethasone. For that purpose, investigators will include a total of 150 patients divided
      in 5 groups: local anaesthetics with placebo, or with dexamethasone 1, 2, 3 and 4 mg.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of analgesia</measure>
    <time_frame>24hour</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of motor block</measure>
    <time_frame>24hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Onset time of action of sensory block</measure>
    <time_frame>1hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Onset time of action of motor block</measure>
    <time_frame>1hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Equivalent morphine consumption in postanesthetic care unit</measure>
    <time_frame>4hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Equivalent morphine consumption on postoperative day 1</measure>
    <time_frame>24hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain scores at rest in postanesthetic care unit (visual analogue scale, 0-10)</measure>
    <time_frame>4hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain scores on movement in postanesthetic care unit (visual analogue scale, 0-10)</measure>
    <time_frame>4hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain scores at rest on postoperative day 1 (visual analogue scale, 0-10)</measure>
    <time_frame>24hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain scores on movement on postoperative day 1 (visual analogue scale, 0-10)</measure>
    <time_frame>24hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of postoperative nausea and vomiting (PONV)</measure>
    <time_frame>24hour</time_frame>
    <description>Presence of PONV (YES/NO)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of pruritus</measure>
    <time_frame>24hour</time_frame>
    <description>Presence of pruritus (YES/NO)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction score on postoperative day 1 (visual analogue scale, 0-10)</measure>
    <time_frame>24hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycemia in postanesthetic care unit (mmol/l)</measure>
    <time_frame>4hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of infection</measure>
    <time_frame>24hour</time_frame>
    <description>Presence of infection (YES/NO)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of infection</measure>
    <time_frame>7 days</time_frame>
    <description>Presence of infection (YES/NO)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of paresthesia</measure>
    <time_frame>7 days</time_frame>
    <description>Presence of paresthesia (YES/NO)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of muscle weakness</measure>
    <time_frame>7 days</time_frame>
    <description>Presence of muscle weakness (YES/NO)</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive ropivacaine 0.5% 15 mls with normal saline 0.9% 2 mls</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dex 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive ropivacaine 0.5% 15 mls with dexamethasone 1 mg in 2 mls</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dex 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive ropivacaine 0.5% 15 mls with dexamethasone 2 mg in 2 mls</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dex 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive ropivacaine 0.5% 15 mls with dexamethasone 3 mg in 2 mls</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dex 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive ropivacaine 0.5% 15 mls with dexamethasone 4 mg in 2 mls</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal saline 0.9% in 2 mls</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone 1 mg</intervention_name>
    <description>Dexamethasone 1 mg in 2 mls</description>
    <arm_group_label>Dex 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone 2 mg</intervention_name>
    <description>Dexamethasone 2 mg in 2 mls</description>
    <arm_group_label>Dex 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone 3 mg</intervention_name>
    <description>Dexamethasone 3 mg in 2 mls</description>
    <arm_group_label>Dex 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone 4 mg</intervention_name>
    <description>Dexamethasone 4 mg in 2 mls</description>
    <arm_group_label>Dex 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine 0.5%</intervention_name>
    <description>Ropivacaine 0.5% 15 mls</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Dex 1</arm_group_label>
    <arm_group_label>Dex 2</arm_group_label>
    <arm_group_label>Dex 3</arm_group_label>
    <arm_group_label>Dex 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients scheduled for elective shoulder arthroscopy

          -  duration of surgery less than 4 hours

        Exclusion Criteria:

          -  allergy to local anaesthetics

          -  history of neck surgery

          -  history of neck radiotherapy

          -  severe respiratory disease

          -  diabetic patient

          -  chronic pain condition

          -  pregnancy

          -  patient suffering from cancer

          -  patient with addicted disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Albrecht, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lausanne University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eric Albrecht, MD</last_name>
    <phone>+41795566341</phone>
    <email>eric.albrecht@chuv.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Lausanne University Hospital</name>
      <address>
        <city>Lausanne</city>
        <state>Vaud</state>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric Albrecht</last_name>
      <phone>+41795566341</phone>
      <email>eric.albrecht@chuv.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <lastchanged_date>June 29, 2016</lastchanged_date>
  <firstreceived_date>June 23, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Universitaire Vaudois</investigator_affiliation>
    <investigator_full_name>Eric Albrecht</investigator_full_name>
    <investigator_title>PD MD, Program director of regional anaesthesia</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
